Additional studies demonstrated dose-dependent responses and increased CD15 expression in leukemia cells, leading to FDA approval of AG-221 for relapsed or refractory AML in adults with IDH2 mutations.76, 77, 78 Similarly, SH1573 was approved for clinical trials in China for the same mutation target in AML75 (Fig. 4). Here, IDH2 is linked to acute myeloid leukemia.